Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis.

Abstract

To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of treatment, the improvement in the fluorescein angiography score and vitritis score was significantly higher in the DEX group than in the non-DEX group. Although the posterior capsule opacification score was exacerbated, the rate of low-dose systemic glucocorticoid was higher and the relapse times were fewer in the DEX group. Therefore, Ozurdex® is an effective and safe option for patients with BU that are refractory to systemic immunosuppressant treatments by controlling vasculitis, stabilizing vitreous inflammation, preventing recurrence, and reducing daily glucocorticoid doses.

• Authors: Tianyu Tao, Shizhao Yang, Daquan He, Zhaohuai Li, Binyao Chen, Lei Zhu, Wenru Su
• Journal: Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 251 Pg. 109633 (06 2023) ISSN: 1521-7035 [Electronic] United States
• PMID: 37150241 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Glucocorticoids
• Dexamethasone

Topics

• Humans
• Glucocorticoids (therapeutic use)
• Cross-Sectional Studies
• Treatment Outcome
• Uveitis (drug therapy)
• Dexamethasone (therapeutic use)
• Behcet Syndrome (complications, drug therapy)
• Retrospective Studies